Kingsley Biotechnology (01548) announced, Eight abstracts of the study sponsored by Legend Biotechnology Co., Ltd. (legend biotechnology, a non wholly-owned subsidiary of the company, whose shares are listed on the NASDAQ Global Select market in the form of American Depositary Shares) have been selected for the 2022 annual meeting of the American Society of Clinical Oncology (ASCO) (2022 annual meeting of ASCO) and the 2022 European hematology Association (EHA) Wuxi Online Offline Communication Information Technology Co.Ltd(300959) mixed meeting (“2022 EHA Wuxi Online Offline Communication Information Technology Co.Ltd(300959) mixed meeting”).
These reports will provide the latest information on the cartitude clinical development plan, which aims to evaluate the safety and efficacy of carvykti (cilta CEL), a chimeric antigen receptor T cell (car-t) therapy targeting B cell maturation antigen (BCMA), in the treatment of multiple myeloma.
The long-term follow-up results of cartitude-1 (two years after the last patient was enrolled) will be presented in the form of posters at the 2022 ASCO annual meeting and the 2022 EHA Wuxi Online Offline Communication Information Technology Co.Ltd(300959) mixed meeting. Cartitude-1 is a phase 1B / 2 study of patients with recurrent or refractory multiple myeloma (R / R mm) who have previously received multiple line therapy. The results support the approval of carvykti by the U.S. Food and Drug Administration (FDA).
The report will also present updates for cartitude-2 study cohort A and cohort B. The purpose of this multi cohort study was to evaluate the safety and efficacy of sidakiolenza in various treatment scenarios of multiple myeloma, including front-line treatment. Cohort a includes patients with multiple myeloma who have progressed and are resistant to lenalidomide after previous line 1 – 3 treatment. The information will be presented in poster form at the 2022 ASCO annual meeting and the 2022 EHA Wuxi Online Offline Communication Information Technology Co.Ltd(300959) mixed meeting.
Cohort B includes patients with early relapse after initial treatment (including proteasome inhibitors and immunomodulator drugs). The information will be displayed in posters at the 2022 ASCO annual meeting and presented in the form of oral report at the 2022 EHA Wuxi Online Offline Communication Information Technology Co.Ltd(300959) mixed meeting. Other information will also be released at the two meetings, including information from the real-world study locommotion, a prospective multinational study of real-world standard treatment for R / R MM patients in routine clinical practice.
Cartitude-1 (nct03548207) is an ongoing phase 1B / 2, open label, single arm, multicenter trial to evaluate the efficacy of sidakiolenza in the treatment of adult patients with recurrent or refractory multiple myeloma who have received at least three lines of previous treatment, including proteasome inhibitor PI, immunomodulator IMID and anti-CD38 monoclonal antibody. Of the 97 patients enrolled in the trial, 99% were resistant to the last-line treatment and 88% were triple resistant (i.e. their tumors had no or no response to IMID, PI and anti-CD38 monoclonal antibody).
Cartitude-2 (nct04133636) is an ongoing phase 2 multi cohort study to evaluate the safety and efficacy of sidakiolenza in various clinical treatment scenarios. Cohort a included patients with multiple myeloma progression, lenalidomide resistance, and no previous use of targeted BCMA drugs after previous 1 – 3-line treatment, including PI and IMID. Cohort B included patients with early recurrence after initial treatment, including PI and IMID. The primary endpoint was the proportion of patients with negative minimal residual disease (MRD).
Locommotion (nct04035226) is a prospective non intervention study that evaluated the safety and efficacy of real-world standard treatment for patients with recurrent or refractory multiple myeloma (R / R mm) in routine clinical practice within 24 months. The purpose of this study was to understand the effectiveness of current standard therapy in R / R MM patients who have received a large number of treatments in the past (reflecting the clinical practice of patients with disease progression after treatment with proteasome inhibitors, immunomodulators and anti-CD38 antibodies in the real world).
